Seeing Is Believing: GSK Pledges To Upgrade Key Antibiotics Plant As Witty Hosts Q3 Call From Singapore
This article was originally published in PharmAsia News
During a celebration to mark GSK’s 40th year in Singapore, CEO Andrew Witty announces new investments in work-horse manufacturing plants and reaffirms openness to share patient data from clinical studies.
You may also be interested in...
AstraZeneca is giving 15 shelved compounds to U.K.-based academics in a collaboration funded by public money that may produce scientific breakthroughs along with thorny IP issues.
GlaxoSmithKline, previously punished for holding back key medical information, is making its huge library of clinical trial data available to scientists in an effort promote drug discovery and show that it hides no secrets.
GlaxoSmithKline announced NDA filings for BRAF inhibitor dabrafenib and MEK inhibitor trametinib in metastatic melanoma on Aug. 3. The two compounds represent one-quarter of the company’s novel oncology agents in clinical development, according to the most recent pipeline update.